Structure-function analyses of cytochrome P450revI involved in reveromycin A biosynthesis and evaluation of the biological activity of its substrate, reveromycin T

J Biol Chem. 2014 Nov 21;289(47):32446-58. doi: 10.1074/jbc.M114.598391. Epub 2014 Sep 25.

Abstract

Numerous cytochrome P450s are involved in secondary metabolite biosynthesis. The biosynthetic gene cluster for reveromycin A (RM-A), which is a promising lead compound with anti-osteoclastic activity, also includes a P450 gene, revI. To understand the roles of P450revI, we comprehensively characterized the enzyme by genetic, kinetic, and structural studies. The revI gene disruptants (ΔrevI) resulted in accumulation of reveromycin T (RM-T), and revI gene complementation restored RM-A production, indicating that the physiological substrate of P450revI is RM-T. Indeed, the purified P450revI catalyzed the C18-hydroxylation of RM-T more efficiently than the other RM derivatives tested. Moreover, the 1.4 Å resolution co-crystal structure of P450revI with RM-T revealed that the substrate binds the enzyme with a folded compact conformation for C18-hydroxylation. To address the structure-enzyme activity relationship, site-directed mutagenesis was performed in P450revI. R190A and R81A mutations, which abolished salt bridge formation with C1 and C24 carboxyl groups of RM-T, respectively, resulted in significant loss of enzyme activity. The interaction between Arg(190) and the C1 carboxyl group of RM-T elucidated why P450revI was unable to catalyze both RM-T 1-methyl ester and RM-T 1-ethyl ester. Moreover, the accumulation of RM-T in ΔrevI mutants enabled us to characterize its biological activity. Our results show that RM-T had stronger anticancer activity and isoleucyl-tRNA synthetase inhibition than RM-A. However, RM-T showed much less anti-osteoclastic activity than RM-A, indicating that hemisuccinate moiety is important for the activity. Structure-based P450revI engineering for novel hydroxylation and subsequent hemisuccinylation will help facilitate the development of RM derivatives with anti-osteoclast activity.

Keywords: Biosynthesis; Crystallography; Cytochrome P450; Enzyme Catalysis; Polyketide; Reveromycin; Secondary Metabolite; Streptomyces.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biocatalysis
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cells, Cultured
  • Crystallography, X-Ray
  • Cytochrome P-450 Enzyme System / chemistry
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P-450 Enzyme System / metabolism*
  • Electrophoresis, Polyacrylamide Gel
  • HeLa Cells
  • Humans
  • Hydroxylation
  • Isoleucine-tRNA Ligase / antagonists & inhibitors
  • Isoleucine-tRNA Ligase / metabolism
  • K562 Cells
  • Kinetics
  • Microbial Viability / drug effects
  • Models, Molecular
  • Molecular Structure
  • Mutation
  • Osteoclasts / cytology
  • Osteoclasts / drug effects
  • Protein Binding
  • Protein Structure, Tertiary
  • Pyrans / chemistry
  • Pyrans / metabolism*
  • Pyrans / pharmacology
  • Spiro Compounds / chemistry
  • Spiro Compounds / metabolism*
  • Spiro Compounds / pharmacology
  • Structure-Activity Relationship
  • Substrate Specificity
  • Tandem Mass Spectrometry

Substances

  • Pyrans
  • Spiro Compounds
  • reveromycin A
  • Cytochrome P-450 Enzyme System
  • cytochrome P-450 107E6 protein, human
  • Isoleucine-tRNA Ligase

Associated data

  • PDB/3WVS